The study, led by Sophie Estienne and colleagues at Nancy University Hospital and the Université de Lorraine, followed 62 patients with confirmed endogenous ACTH-independent hypercortisolism, a condition in which the adrenal glands secrete cortisol autonomously rather than in response to adrenocorticotropic hormone. All patients were managed at a single center between January 2019 and January 2024. The researchers divided them into three groups: 42 patients who underwent adrenalectomy, the surgical removal of cortisol-producing adrenal tissue; 13 who received medical therapy with anticortisolic drugs; and 7 who were kept under observation without immediate intervention. Metabolic markers — body mass index, blood pressure, blood glucose and diabetes status, lipid profile, and liver parameters — were then tracked at baseline, six months, and twelve months.

ACTH-independent hypercortisolism encompasses a spectrum of adrenal disorders, from overt Cushing’s syndrome caused by a single adrenocortical adenoma to more indolent conditions such as mild autonomous cortisol secretion, or MACS, detected incidentally on imaging, and primary bilateral macronodular adrenocortical hyperplasia, known as PBMAH, in which both adrenal glands enlarge and secrete hormone autonomously. Prolonged cortisol excess is well established as a driver of morbidity: it promotes central obesity, hypertension, insulin resistance and type 2 diabetes, dyslipidemia, and fatty liver disease, and it ultimately raises cardiovascular mortality. Because of this burden, normalizing cortisol exposure — whether by removing the source surgically or suppressing it pharmacologically — is considered the most effective way to limit complications. Yet, as the French team notes, few studies have directly compared the metabolic consequences of the two strategies head-to-head.

The short-term results were broadly reassuring for both active treatments. At the six-month mark, patients in both the surgery and medication groups showed improvements in cortisol levels, weight, blood pressure, lipid profile, diabetes control, and liver parameters compared with their baseline values. In other words, whichever route clinicians chose to reduce cortisol burden, the downstream metabolic machinery began to respond. The metabolic syndrome that accompanies chronic hypercortisolism is, to a meaningful degree, reversible once the hormonal driver is controlled.

But one difference stood out — and it persisted. Weight loss, measured as change in body mass index, was significantly greater in the medication group. Over the first six months, medically treated patients lost an average of 1.61 kilograms per square meter of body surface, while surgically treated patients actually gained a slight average of 0.25 kilograms per square meter. That gap had not closed by twelve months, suggesting it reflects a genuine divergence in how the two treatment modalities affect body composition rather than a transient postoperative fluctuation. For all other measured metabolic parameters — blood pressure, glucose metabolism, lipids, and liver markers — the study found no significant difference between the surgery and medication arms.

The most striking findings emerged when the researchers broke the results down by the underlying cause of hypercortisolism. Among patients with PBMAH, those treated medically fared considerably better on several fronts than those who underwent surgery. Medically managed PBMAH patients saw their BMI fall by an average of 1.98 kilograms per square meter, compared with a gain of 0.68 in the operated group. Their blood pressure also improved dramatically: systolic pressure dropped by an average of 11.6 millimeters of mercury, versus an increase of 3 in the surgical group, while diastolic pressure fell by 4.5 millimeters of mercury against a rise of 5 in operated patients. For the other etiologies — such as unilateral adenomas treated by adrenalectomy — the researchers observed no significant differences between treatment strategies.

The authors’ conclusion is measured but clinically consequential: medical treatment appears more effective than surgery for improving weight in ACTH-independent hypercortisolism, particularly in patients with PBMAH, while the choice of treatment modality seems to have little impact on other short-term metabolic outcomes. The result makes physiological sense. PBMAH is a bilateral disease, so definitive surgical treatment typically involves bilateral adrenalectomy, leaving the patient in permanent adrenal insufficiency requiring lifelong glucocorticoid and mineralocorticoid replacement — a regimen that itself promotes weight gain and is notoriously difficult to titrate. Unilateral surgery in bilateral disease may also remove only part of the cortisol excess, and postoperative replacement steroid exposure can partially offset metabolic gains. Chronic medical therapy, by contrast, gradually titrates cortisol blockade while leaving the adrenal axis partially intact, potentially allowing a smoother return to eucortisolism without replacement-induced overshoot.

The study has limitations that the authors themselves acknowledge by design. It is retrospective, observational, and monocentric, with modest group sizes — particularly the 13 medically treated patients and 7 observed controls — and treatment allocation was not randomized. Patients selected for medical therapy often differ systematically from those sent to surgery: bilateral disease, older age, higher surgical risk, or patient preference may all have concentrated certain metabolic phenotypes in the medication arm. The relatively small observation group prevents firm conclusions about watchful waiting. The findings are also restricted to short- and medium-term follow-up of twelve months; whether the weight advantage of medical therapy translates into reduced cardiovascular events, improved bone mineral density, or better long-term survival remains untested.

Nevertheless, the work speaks to a rapidly evolving therapeutic landscape. For decades, adrenalectomy was essentially the only curative option for cortisol-producing adrenal disease, and the choice was binary: operate or watch. The emergence of effective steroidogenesis inhibitors and newer cortisol-modulating agents has changed that calculus, giving endocrinologists a genuine pharmacological alternative even for bilateral disease. This study is among the first to compare the two strategies specifically through a metabolic lens, rather than focusing solely on biochemical remission rates. Its message — that the goal of treatment should not merely be a normalized cortisol number but a demonstrably improved metabolic profile — adds a patient-centered dimension to treatment selection.

For the substantial population of patients with incidental adrenal findings and mild autonomous cortisol secretion, and for those with PBMAH facing the prospect of bilateral surgery, the results offer grounds for a more nuanced conversation. The evidence suggests that for patients whose primary threat is metabolic — obesity, hypertension, diabetes — medical cortisol control, where feasible, may deliver better weight and blood pressure outcomes than extirpative surgery, at least over the first year. Larger, prospective, and ideally randomized comparisons with longer follow-up will be needed to confirm whether these early metabolic signals endure, but the French data provide a compelling first head-to-head signal that, in the metabolic battle against excess cortisol, sometimes the better tool is a pill rather than a scalpel.

The study, published in the Journal of Clinical Investigation Insight, explored how intermittent administration of GLP-1 drugs affected weight loss outcomes in an animal model. Using overweight mice as subjects, researchers compared a regimen of continuous semaglutide dosing over several months against a stop-start pattern involving cycles of two weeks on treatment followed by two weeks off. Their findings revealed that while both groups initially experienced comparable reductions in body weight, the mice subjected to intermittent dosing failed to maintain these benefits. Specifically, each hiatus from the drug led to rapid weight regain, predominantly through fat accumulation. This rebound effect attenuated the drug’s impact upon reinitiation, culminating in an overall diminished weight loss compared to continuous treatment.

This phenomenon of diminishing returns after repeated discontinuation has profound clinical implications, especially in the context of the GLP-1 drug market’s explosive growth. Approximately one in eight adults in the United States reports current or past use of GLP-1 receptor agonists for weight loss, but adherence remains a major barrier. Studies show that over half of the patients discontinue therapy within two years, often resuming treatment after a lapse. The new research suggests that such stop-start patterns could blunt the drugs’ long-term benefits, emphasizing the necessity of sustained commitment to therapy.

Delving into the mechanistic insights, the research highlighted alterations in body composition as a pivotal factor driving the observed reduced efficacy. Weight loss induced by GLP-1 receptor agonists characteristically comprises a combination of fat mass reduction and muscle mass catabolism—historically estimated at roughly 60% fat loss and 40% muscle loss in mice. However, during periods of drug cessation, regained weight consists almost exclusively of fat, not muscle. As treatment resumes, the altered muscle-to-fat ratio presents a new metabolic challenge. Magnetic resonance imaging (MRI) analyses suggested that the organism hits a “muscle floor,” beyond which further muscle loss is physiologically resisted to maintain critical bodily functions, thus limiting further reductions in fat mass during subsequent treatment cycles.

This metabolic ceiling implies that the body’s homeostatic mechanisms prioritize muscle preservation when confronted with repeated weight cycling, which may explain why GLP-1 therapy benefits taper with intermittent use. Dr. Thomas H. Leung, senior author on the study and a professor at Penn Medicine, elucidates this biological threshold, highlighting the body’s adaptive resistance to inconsistent pharmacological interventions in weight management.

The findings align with broader pharmacodynamic principles observed in other medications requiring regular dosing for optimal effect. For example, drugs like minoxidil, employed for hair regrowth, similarly demonstrate reduced effectiveness when adherence falters. GLP-1 receptor agonists may likewise require uninterrupted administration to maintain pharmacological momentum and prevent internal compensatory pathways from undermining their efficacy.

Beyond the dose timing nuances, this new evidence underscores the critical role of preserving lean muscle mass during weight loss interventions. The study’s authors advocate for integrated strategies that combine GLP-1 pharmacotherapy with lifestyle modifications focused on exercise and optimal nutrition to mitigate muscle loss. Maintaining muscle mass could prevent or delay the onset of this “muscle floor” and sustain weight loss efficacy, a hypothesis warranting further clinical investigation.

Another important dimension for future research involves extending these findings to other next-generation incretin therapies such as tirzepatide (brand name Zepbound), which acts on both GLP-1 and GIP receptors. Given tirzepatide’s dual mechanism and emerging clinical prominence, investigating whether it exhibits similar patterns of diminishing returns with inconsistent use holds significant translational value.

The demonstrated interplay between drug adherence, body composition shifts, and pharmacological outcomes could also inform personalized medicine approaches. Physicians may need to engage in nuanced discussions with patients initiating GLP-1 therapies to set realistic expectations and emphasize the importance of long-term commitment. For some patients, who find daily or weekly dosing challenging, alternative strategies or adjunct therapies might be considered to optimize results.

While these preclinical insights are robust, confirmation through comprehensive human clinical trials is essential to translate the findings into standard clinical guidelines. Such studies should incorporate advanced body composition assessments and longitudinal adherence monitoring to elucidate whether the muscle floor phenomenon and weight regain patterns observed in mice similarly constrain weight loss trajectories in human patients.

In summary, this new research from Penn Medicine casts a spotlight on a critical underappreciated factor in GLP-1 receptor agonist therapy: consistency is key. The efficacy of these powerful pharmaceuticals appears contingent on uninterrupted use to circumvent metabolic adaptations that limit weight loss. As GLP-1 drugs become increasingly mainstream in the fight against obesity, integrating pharmacotherapy with nutritional and exercise interventions, alongside careful patient adherence counseling, will be paramount to harnessing their full therapeutic potential.

Subject of Research: Animals
Article Title: Inconsistent GLP-1 receptor agonist use diminishes weight loss efficacy through altered body composition: Insights from preclinical models
News Publication Date: Not specified in the source
Web References:
– https://insight.jci.org/articles/view/205174
– https://www.med.upenn.edu/
– https://www.upenn.edu/
– https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/
– https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829779
Keywords: GLP-1 receptor agonists, weight loss, semaglutide, drug adherence, obesity, body composition, muscle floor, metabolic adaptation, incretin therapies, tirzepatide, pharmacodynamics, Penn Medicine

The researchers examined a substantial demographic, concentrating on Americans aged 65 years and older. Among this population, they found that one in nine individuals who had faced parental divorce during their formative years reported being diagnosed with a stroke. In contrast, only one in 15 individuals whose parents remained together throughout their childhood exhibited a similar diagnosis. These alarming statistics underscore the profound impact that familial instability can exert on long-term health outcomes.

Mary Kate Schilke, the study’s first author and a university lecturer in the Psychology Department at Tyndale University, emphasized that even after adjusting for various known risk factors associated with stroke—such as smoking, physical inactivity, lower income and education levels, diabetes, depression, and a lack of social support—individuals who experienced parental divorce still faced a staggering 61% higher likelihood of stroke. This significant figure not only emphasizes the importance of considering familial background in assessing health risks but also raises questions about the underlying mechanisms contributing to this association.

The findings indicate that the strong correlation between parental divorce and stroke risk is not solely an anomaly but mirrors the effects of other established factors recognized in the medical community, such as diabetes and depression. This study builds upon previous research conducted nearly a decade ago, revealing similar outcomes in an entirely different population-based sample, thus affirming the consistency and validity of these findings.

One of the key challenges noted by the researchers is understanding the exact reasons behind this persistent link between parental divorce and later health complications. Senior author Esme Fuller-Thomson, a professor at the Factor-Inwentash Faculty of Social Work and the director of the Institute of Life Course and Aging at the University of Toronto, pointed out that while survey-based studies cannot definitively establish causality, the hope remains that these consistent findings could inspire further investigation into the mechanisms at play.

Importantly, the researchers took a comprehensive approach by excluding participants with a history of childhood abuse, which could potentially confound the results. Interestingly, the analysis revealed that even among individuals who had not experienced physical or sexual abuse in childhood and who had at least one adult present in their lives that made them feel safe, the risk of stroke remained significantly higher for those whose parents had divorced. This surprising finding suggests that the repercussions of parental divorce might transcend direct adverse childhood experiences, indicating deeper systemic influences.

Moreover, the study found that other forms of childhood adversity, including emotional abuse, neglect, household mental illness, substance abuse, or exposure to domestic violence, did not show a significant association with stroke risk. This specificity indicates that the psychological and physiological ramifications of parental divorce may be distinct from other types of childhood trauma, warranting focused attention in both research and clinical settings.

As the research community grapples with understanding the reasons behind these associations, the authors speculate on potential biological and sociological constructs contributing to heightened stroke risk among this demographic. From a biological standpoint, the stress associated with parental conflict and eventual separation during childhood may lead to sustained overproduction of stress hormones. This chronic physiological stress response could then impair the developing brain’s ability to manage adversity later in life, ultimately manifesting in physical health issues such as stroke.

The implications of this research extend beyond the individual, shedding light on broader societal patterns and healthcare considerations. If future studies continue to corroborate these associations between parental divorce and health risks, they could fundamentally reshape how healthcare professionals approach patient assessments and preventive strategies. Recognizing the potential influence of childhood family dynamics may provide an essential lens through which healthcare systems can enhance their outreach efforts for stroke prevention and education initiatives.

As the discourse surrounding mental and physical health continues to evolve, the findings from this study compel us to reconsider the long-term effects of childhood experiences on adult health. The growing awareness of how familial structures shape individual well-being is more crucial than ever, especially as society witnesses increasing divorce rates and the challenges those families face.

The optimism for further research is palpable, as the authors are hopeful that their findings will serve as a clarion call for interdisciplinary collaboration. By drawing attention to this underexplored area, they aim to invigorate interest among scholars, clinicians, and public health advocates. Greater understanding of how childhood experiences shape health trajectories could ultimately lead to more comprehensive strategies for health promotion and education, paving the way for better health outcomes in populations affected by familial instability.

In conclusion, the study published in PLOS One serves as a reminder of the intricate interplay between childhood experiences and adult health. The revelations regarding the association between parental divorce and increased stroke risk call for a deeper exploration into the underlying mechanisms, encouraging a holistic approach to health that acknowledges the significance of our early familial environments in shaping our long-term well-being.

Subject of Research: The impact of parental divorce on stroke risk in older adults.
Article Title: Parental divorce’s long shadow: Elevated stroke risk among older Americans.
News Publication Date: 22-Jan-2025.
Web References: DOI Link
References: N/A
Image Credits: N/A

Keywords: parental divorce, stroke risk, childhood adversity, health outcomes, psychosocial factors, aging, stress response, health research.